Executive Summary Multiple-of-Medicare (“MoM”) repricing is a popular and common cost containment strategy used by many plans and repricing companies. Renalogic has intentionally chosen to stay away from MoM methods because of the high risk of litigation. That risk has…
Newsweek Magazine ArticleBy: David H. Freedman Before the pandemic, the plan would have seemed like something ripped from a distant dystopian future in which the human race fully surrenders to Big Tech. On the April 10 online document, the logos…
The central mission of Renalogic has always been to drive positive change for kidney disease and help members thrive while living with chronic conditions. These values hold even more now with our member’s lives so significantly impacted by the COVID-19…
Health Benefits Risk Management at the Intersection of Monopoly and Intensive Regulation The dialysis sector is an intensified microcosm of the American health care system, and that’s bad for self-insured plans in particular. On the one hand, the dialysis marketplace…
As the leader in chronic kidney disease (“CKD”) case management for self-funded employers, we are thrilled by the new Executive Order directing Medicare to develop payment models encouraging providers to identify and treat Medicare beneficiaries who have late-stage CKD, to…
This is the second in a series of posts on the DaVita and related dialysis sector litigation. The first post is available here Intro: As noted in my previous post, the DaVita cases are all principally based on the Medicare…
